Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. During the trial, patients with focal seizures (n=19) showed a median 25.2 We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. The millions of people afflicted with PTSD may soon have access to MDMA therapy, and we believe the millions suffering from TBI may experience similar relief in the future.”.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. While its psilocybin and MDMA trials progress, the company is expanding its psychedelics research laboratory.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MAY 29, 2022

In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 4] In April 2021, a separate study from the New England Journal of Medicine demonstrated the efficacy of psilocybin in reducing symptoms of depression. [5] Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. Data suggests that the market has inflated from JPY4 billion (USD$3 billion) in 2019 to JPY17 billion (USD$13 billion) in 2022.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

JULY 6, 2021

July 06, 2021 08:30 ET | Source: Ehave. MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Dr. Bankole Johnson was featured in a March 5 th 2021 Forbes article, “Dr. We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.”

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. 3 Nature Aging | VOL 1 | July 2021 | p. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 2, 2021

Testing is scheduled to begin in the second half of September 2021. The College, part of the State University of New York (SUNY) system, is aligned with SUNY’s vaccination mandate, which requires all on-campus students to be fully vaccinated against COVID-19 by September 27, 2021. Hayward, president and CEO of Applied DNA.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

AUGUST 3, 2021

– Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs’ safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening –. Fiscal 2021 Third Quarter Financial Results and Investor Conference Call. Food and Drug Administration (U.S.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Nov 24 2021. Journal of Clinical Gynecology and Obstetrics, North Amer, 0 Nov 2021.

Patients 98

Patients Education Marijuana Therapy 98

Healer

MARCH 26, 2021

March 19, 2021. The results were published in the Cureus Journal of Medical Science, an open-access general medical journal known for its use of crowdsourcing in its peer-review process. . The researchers stressed the need for large, well-designed clinical trials. Others aren’t so sure. Written by Hannah Laclaire.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

OCTOBER 12, 2021

Mary Hartnett, Director of Medical Services at Sarah Lawrence College, stated, “safeCircle was our choice given the convenience of its on-site sample collection process, access to high-sensitivity RT-PCR-based testing with rapid turnaround times, ability to scale with our needs, and capacity to ease our administrative burdens.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Canna Care Docs

DECEMBER 16, 2020

The New Year is fast approaching, and if you’re not feeling entirely hopeful about 2021, you’re certainly not alone. The difference is that medical patients may have access to higher dosages, among other benefits depending on their state, and receive a higher level of service to match them with the best products for their symptoms.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

DECEMBER 21, 2021

SAN DIEGO–(BUSINESS WIRE)– $DFCO #CleanEnergy — Dalrada Corporation (OTCQB: DFCO , “Dalrada”) would like to express its sincere appreciation for its investors, shareholders, staff and followers for their support throughout 2021. from 2021 to 2028. from 2021 to 2030. billion (2020).

Research and Development 52

Research and Development Supply Chain Data Business 52

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is the largest national chain of ketamine infusion clinics in the United States and will add to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers in California and Arizona , cementing its position as the leading and largest health provider in the country.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. However, despite the increased use of MCs in children, there is limited data regarding their safety and efficacy in this population for those different indications 11. Data extraction. Stolar & Ilan Matok. Metrics details.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 17, 2021

deletion syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The trial is currently registered with the Australian New Zealand Clinical Trials Registry (ANZCTR).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Therapy 52

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. Steve Barbera to Vice President, Market Access. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52

Canna Law Blog

NOVEMBER 6, 2021

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. For two decades, U.S.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

The Cannigma

JANUARY 13, 2023

A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. 7 A 2021 study of a medical cannabis cohort reported that high THC / low CBD flower was the most preferred cannabis type in migraine patients.

Terpenes 132

Terpenes Strains THC Treatment 132

The Cannigma

MARCH 25, 2021

When the law changed in the UK in 2018, I was humbled by the efforts of those who suffer on a daily basis to achieve legal access to medicinal cannabis. These qualities are necessary to ensure that the private medical cannabis space conducts itself with compassion and respect for those who are accessing medication through it.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

OCTOBER 1, 2021

Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 2021 at 9:00 a.m. Eastern time. www.youtube.com/channelchek. www.youtube.com/channelchek. About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 29, 2021

Published on November 30, 2021. The potential real-life impact – keeping in mind that these data were generated under stringent clinical trial conditions and without any tailoring to the specific needs of the individual – could be even more transformative for those patients suffering from TRD. 18 articles.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JUNE 4, 2021

This list is focused on those who have had the largest impact for 2021. . Tim Ferriss is Psychedelics Invest’s number one most influential person for 2021 because of his support through his funding, utilization of his multiple massive social outlets, and his continued balanced message about the efficacy and realities of psychedelic medicines.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51